Drug intelligence / Profile preview

alemtuzumab + cyclophosphamide + fludarabine

Development stage: Unknown
Lead developer: University of Cambridge
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination chemotherapy regimen consisting of alemtuzumab (anti-CD52 monoclonal antibody), cyclophosphamide (alkylating agent), and fludarabine (purine nucleoside analog). This regimen is primarily used for treating relapsed or refractory chronic lymphocytic leukemia (CLL), especially in high-risk patients with features such as fludarabine refractoriness, complex karyotype, or chromosome 17p abnormalities.

Other names: Fludarabine, Cyclophosphamide, and Alemtuzumab

Targets

CD52 (CD52 Antigen)DNA

Beyond the preview

Go deeper on alemtuzumab + cyclophosphamide + fludarabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alemtuzumab + cyclophosphamide + fludarabine.

Explore the full profile